Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia

Carlo Salvarani(Azienda Sanitaria Unità Locale di Reggio Emilia)

JAMA Internal Medicine

October 20, 2020

10.1001/jamainternmed.2020.6615

Cited by 732

Related Papers

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study

|Clinical Rheumatology|2018|82

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-<i>α</i> Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network

|Mediators of Inflammation|2020|49

Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease

|Frontiers in Pharmacology|2019|45